Navigation Links
Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting
Date:5/15/2008

ested to study Abbott's Bcl-2 family protein inhibitors, which is an indication of the potential value that ABT-263 might bring to the cancer research field," said John Leonard, M.D., senior vice president, Pharmaceuticals, Research and Development, Abbott. "We have built an early stage pipeline that targets the processes that cancers need to survive and we're looking forward to advancing our work in this area."

Presentation highlights include:

-- A Phase I Study Evaluating the Safety, Pharmacokinetics, and Efficacy

of ABT-263 in Subjects With Refractory or Relapsed Lymphoid

Malignancies

-- Reduction in Platelet Counts as a Mechanistic Biomarker and Guide for

Adaptive Dose-escalation in Phase I Studies of the Bcl-2 Family

Inhibitor ABT-263

-- Dynamic Contrast Enhanced MRI (DCE MRI) for Assessment of Effects of

Anti-Angiogenic Therapy: Comparison of the Transfer Constant (Ktrans)

to Blood Flow and Permeability Derived by a Distributed Parameter

Model

-- Relationship of Dose of ABT-869 on Biomarkers of Angiogenesis and

Their Correlation With Pharmacodynamic (PD) Outcome

Study Background and Results

ABT-263

Thirty patients with refractory or relapsed lymphoid malignancies have been enrolled in an ongoing Phase I study evaluating safety, pharmacokinetics and efficacy. Subjects received ABT-263 orally once daily for 14 consecutive days followed by seven days off drug in each cycle of therapy. Results showed that ABT-263 had an acceptable side-effect profile at the seven-dose (10, 20, 40, 80, 160, 225 and 315 mg) cohort levels and showed evidence of anti-tumor activity. Researchers observed 99 percent and 36 percent tumor reduction in two patients with bulky chronic lymphocytic leukemia (CLL). Another patient with bulky CLL/small lymphocytic lymphoma (SLL) experienced a 75 percent reduction and a patient with follicular lymphom
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Abbott to Present at Citi Investment Research Global Health Care Conference
2. Abbott to Present at Morgan Stanley Global Healthcare Unplugged Conference
3. Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
4. Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook
5. Innovative Diagnostic Instrument Introduced by Abbott for Low- to Mid-Volume Laboratory Market Segment
6. Abbott FreeStyle Freedom(R) Lite Blood Glucose Monitoring System Now Available With No Coding for People With Diabetes
7. Abbott Hosts Conference Call for First-Quarter Earnings
8. Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
9. FDA Approves Abbotts FreeStyle Navigator(R) Continuous Glucose Monitoring System
10. Abbott Receives CE Mark for Smaller-Size XIENCE(TM) V Drug Eluting Stent
11. Abbott, Genentech and WEHI Collaborate to Research and Develop New Anti-Cancer Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... EcoHealth Alliance, a nonprofit organization that focuses on conservation ... today examining the current state of knowledge of the ... improved global surveillance strategies to combat the emergence of ... in West Africa that has claimed the lives of ... According to the World Health Organization (WHO), the ...
(Date:4/17/2014)... Spending time online has the potential to ward off ... according to research published online in The ... Sciences . In the article " Internet Use ... States: A Longitudinal Analysis ," the authors report that ... by 33 percent among their study sample. , ...
(Date:4/17/2014)... Council scientists and their partners have found that their ... the transmission of multiple sexually transmitted infections (STIs) in ... simplex virus 2 (HSV-2), and human papillomavirus (HPV). The ... gel is effective against multiple strains of HIV, and ... all three viruses of at least eight hours prior ...
(Date:4/17/2014)... WINSTON-SALEM, N.C. April 17, 2014 Meaningful ... from advanced cancer of the abdomen when treated ... HIPEC, according to a first-of-its-size analysis by physicians ... Forest Baptist has the largest reported, single-center experience ... Edward A. Levine, M.D., and analysis of 20 ...
(Date:4/17/2014)... D.C. -- The world is less than 40 years ... implications for people and governments, according to a top ... the first time in human history, food production will ... of land, water and energy," said Dr. Fred Davies, ... security. "Food issues could become as politically destabilizing by ...
Breaking Medicine News(10 mins):Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Internet use may cut retirees' depression 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:Food shortages could be most critical world issue by mid-century 2
... by the Dana-Farber Cancer Institute shows more than half ... developing treatment-related infertility problems.// ,Nearly 700 members ... were 40 years old or younger were surveyed. More ... they were concerned about being infertile as a result ...
... by nurses and dieticians have been found effective in ... shown they work only when these health professionals are ... at a program in which patients received their medications ... and dieticians on factors aimed at improving their cardiovascular ...
... therapeutic option for patients with complicated type 1 diabetes, ... // Now, a new study finds ... worse survival than patients on the transplant waiting list ... Association supports a pancreatic transplant for patients who have ...
... have identified a molecule that may help older people ... cells, called satellite cells, that line the outside of ... to form new muscle tissue. They also generate new ... cells respond when a certain protein called Notch is ...
... reports, patients who were treated for depression responded better ... in their blood.// ,An increasing amount of research ... depression, but the specifics have not been understood. Researchers ... vitamin B12 and the treatment of depression. ,The ...
... suggests a common antipsychotic drug might have caused a pulmonary ... pulmonary embolism results when a blood clot that developed elsewhere ... be deadly. Antipsychotic drugs have been linked to an increased ... shown an association between blood clots and the drug clozapine. ...
Cached Medicine News:Health News:Pancreas Transplant for Diabetics 2
(Date:1/15/2014)... 15, 2014  According to Millennium Research Group (MRG), ... the United States and ... will expand moderately through 2022, with embolization particles ... increasing interest in drug-eluting beads (DEBs) and radioembolization ...
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... 2 data continue to show encouraging anti-tumor activity in,non- small cell ... ... XL647 administration, SAN FRANCISCO, Oct. 24 Exelixis, Inc.,(Nasdaq: ... study of XL647,an inhibitor of EGFR, HER2 and VEGFR kinases, in ...
... Clinical Studies TAX 323 and TAX 324 Published, ... that results of two clinical studies demonstrating that,Taxotere(R) ... fluorouracil for induction therapy, significantly improved overall,survival (OS) ... of,the head and neck (SCCHN) are published in ...
Cached Medicine Technology:Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference 2Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference 3Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference 4Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference 5Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 2Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 3Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 4Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 5Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 6Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 7
... Exceptional comfort for those with ... Toric soft contact lenses let you enjoy ... other soft toric lensa difference youll especially ... throughout the day., This exceptional level of ...
Frequency 55 Toric monthly soft toric lenses....
Acuvue Toric is an exceptionally comfortable soft contact lens made especially for people with astigmatism. The Acuvue Toric lens is designed to comfortably fit the unique shape of your eye....
C 2.3K with lightweight headband: the practical alternative for spectacle-wearers. Delivered in protective designer case....
Medicine Products: